Kringle Pharma (4884) Stock Overview

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

4884 Stock Information

Symbol

4884

Address

207 Saito Bio IncubatorIbaraki, 567-0085Japan

Founded

Trading hours

Website

https://www.kringle-pharma.com

Country

🇯🇵 Japan

Phone Number

81 7 2641 8739

Kringle Pharma (4884) Price Chart

Kringle Pharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$5.83	N/A
Market Cap	$35.25M	N/A
Shares Outstanding	6.05M	24.61%
Employees	13.00	N/A
Shareholder Equity	2.02B	-27.52%

Valuation	2023	Change
P/S Ratio	72.61	N/A
P/B Ratio	0.02	N/A

Growth	2023	Change
Return on Equity	-0.0030	N/A

Earnings	2023	Change
Revenue	$485.44K	N/A
Earnings	-$5.99M	N/A
Gross Margin	1.00	N/A
Operating Margin	-12.83	N/A
Net income margin	-12.33	N/A

Financial Strength	2023	Change
Total Assets	$18.36M	N/A
Cash on Hand	$14.98M	N/A
Debt to Equity	0.0021	96.32%
Current Ratio	$12.52	-36.44%